A cup of coffee with … Kelly Knaapen-Arts
Arnold & Siedsma was one of the first companies that became part of the Pivot Park community in 2012.
Read more
New at Pivot Park – GlycoMScan
Recently GlycoMScan has opened their company’s doors in the van Leeuwenhoek building’s basement. GlycoMScan offers services in mass spectrometry, from screening of small molecules to absolute quantification in complex biological matrices.
Read more
New Dutch Q fever test comes out on top in Australian research
The Q-detect™ test, developed by the Dutch Innatoss, turns out to be the best test by far for Q fever screening. The results were presented at the European microbiology conference ECCMID in Madrid.
Read more
Glycostem moves into new lab, production and HQ facility
Glycostem relocated to its new facilities at Pivot Park, Oss, Netherlands. Collectively comprising nearly 500 square meters, the premises include the company’s stateof-the-art laboratory, production facility and administrative HQ.
Read more
NTRC expands SynergyFinder™ platform with triple combination testing
NTRC’s SynergyFinder™ platform allows parallel in vitro screening of combinations and distinguishes additive from synergistic effects.
Read more
Prexton Therapeutics acquired by Lundbeck
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced March 16th the signing of a definitive agreement in which Lundbeck will acquire Prexton.
Read more
Ardena acquires ChemConnection adding API expertise
Contract development and manufacturing organisation (CDMO) Ardena has acquired ChemConnection.
Read more
InProcess-LSP ontvangt financiering voor nieuwe testtechniek ‘nanomedicijnen’
Life sciences-start-up InProcess-LSP haalt een investering op bij de Brabantse Ontwikkelings Maatschappij (BOM) voor de verdere ontwikkeling van de NanoFlowSizer.
Read more
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
Aduro Biotech announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase I clinical trial of its anti-CD27 antibody.
Read more